Clinical Trials in Miami

Showing 3341-3360 of 9,821 trials

A Study of LY3473329 in Participants With Impaired and Normal Renal Function

NCT05778864

The main purpose of this study is to assess the amount of study drug (LY3473329) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to participants with normal renal function. The safety and tolerability of LY3473329 will also be evaluated in these participants. The study will last up to 8 weeks including screening period.

Renal Insufficiency

Eli Lilly and Company47 participantsStarted Mar 2023

Edgewater, Florida, United States • Miami, Florida, United States • Orlando, Florida, United States +1 more locations

COMPLETEDPhase 3< 1 mile

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

NCT05420961

This a study of V116 in adults ≥50 years of age who previously received a pneumococcal vaccination ≥1 year before enrollment. The primary objectives of this study are to evaluate the safety, tolerability, and immunogenicity of V116.

Pneumonia, Pneumococcal

Merck Sharp & Dohme LLC717 participantsStarted Jul 2022

Birmingham, Alabama, United States • Glendale, Arizona, United States • Tempe, Arizona, United States +48 more locations

A Study of LY3473329 in Participants With Impaired and Normal Renal Function

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

Find Trials by Condition in Miami

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19

A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

Pediatric Arthritis Study of Certolizumab Pegol

Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms